The Clinical Core of the Pacific Northwest (PNW) Prostate Cancer SPORE will support multiple areas relevant to clinical research, including independent clinical research trials spawning from the Major Projects, biospecimen acquisition, a repository for clinical data, and advocacy activities. Specifically, the 4 major aims are:
Specific Aim 1 : To design, execute, accrue to, and othen/vise facilitate the conduct and timely completion of clinical trials relevant to the Major SPORE projects and cores. Clinical investigators from the University of Washington (UW), the University of British Columbia (UBC), and Oregon Health and Science University (OHSU) will participate in this aspect of the core. New clinical trials are planned specific to Projects 2, 3, 4, and 5. There is a renewed effort to improve minority awareness and accrual to these clinical trials.
Specific Aim 2. To design, direct, and assist in patient recruitment for biospecimen acquisition. Specifically, this will support the logistical aspects of consenting patients and actual acquisition of the biospecimens, including emphasis on patient accrual to the rapid tumor autopsy program.
Specific Aim 3. To continue to direct, support, and enhance CAISIS, our repository of clinical and patient-reported data to support clinical and translational prostate cancer research across the consortium. Key initiatives include Improving the efficiency of data collection, the quality and completeness of the data, and the ability to share data with other investigators and other SPOREs in prostate cancer. We will ensure access to CAISIS data for research across PNW SPORE sites.
Specific Aim 4. To ensure that SPORE Major and Developmental Projects maintain a patient-centered focus, we will support and engage the SPORE Advocacy Committee in the activities of the SPORE. The Advocacy Committee will aid in increasing dissemination of information in regards to clinical trials to prostate cancer support groups and minority patient populations. Advocacy Committee members will set research priority areas that influence selection of funded Developmental Projects.

Public Health Relevance

The Clinical Core is essential to conducting translational clinical research and accomplishing SPORE project aims. In addition, our data repository, CAISIS, will provide ongoing outcomes data that annotate specimens in the Biospecimen Core. These specimens, although useful in and of themselves, have increased value when there is detailed information about prior therapies, patterns of disease, and outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA097186-14S1
Application #
9337994
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Program Officer
Hruszkewycz, Andrew M
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
14
Fiscal Year
2016
Total Cost
$522,676
Indirect Cost
$39,900
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201
Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432
Schweizer, Michael T; Haugk, Kathleen; McKiernan, Jožefa S et al. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One 13:e0198389
Peacock, James W; Takeuchi, Ario; Hayashi, Norihiro et al. (2018) SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 10:219-238
Pollan, Sara G; Huang, Fangjin; Sperger, Jamie M et al. (2018) Regulation of inside-out ?1-integrin activation by CDCP1. Oncogene 37:2817-2836
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Schweizer, Michael T; Hancock, Michael L; Getzenberg, Robert H et al. (2018) Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian J Androl 20:405-406
Yan, Qingxiang; Bantis, Leonidas E; Stanford, Janet L et al. (2018) Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. Stat Med 37:627-642
Lam, Hung-Ming; Nguyen, Holly M; Corey, Eva (2018) Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. Methods Mol Biol 1786:1-27
Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167

Showing the most recent 10 out of 400 publications